Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation

Abstract

The clinical relevance of lipoprotein(a) (Lp(a)) as a cardiovascular risk factor is currently underestimated. The aim of our study was to assess the influence of increased Lp(a) values on the development and severity of coronary artery disease (CAD).In our retrospective analysis of 31,274 patients, who were hospitalized for the first time, we compared patients with isolated increased Lp(a) (>110mg/dl) and normal Lp(a) (<30mg/dl), with increased Lp(a) concentrations (30-60mg/dl, 61-90mg/dl, 91-110mg/dl), and in a third analysis with additionally increased LDL cholesterol and HbA1c values.Patients with high Lp(a) levels showed a significantly higher incidence of advanced CAD with a three-vessel disease being present in 50.2 vs. 25.1%. Patients with high Lp(a) levels had a significantly more frequent history of myocardial infarction (34.6 vs. 16.6%, p<0.001), surgical myocardial revascularization (40.8 vs. 20.8%, p<0.001) and percutaneous coronary intervention (55.3 vs. 33.6%, p<0.001). In addition, there was a marked difference in gender to the disadvantage of male patients regarding development and severity of CAD. CAD risk (Odds ratio) was increased 5.5-fold in patients with Lp(a) ≥110mg/dl. Additionally elevated LDL and HbA1c levels were not associated with increased manifestation and severity of CAD.High Lp(a) concentration leads to an increased manifestation and severity of coronary artery disease. Additional risk factors do not aggravate manifestation of CAD.